SYUP Stock Overview
Shanghai Yutong Pharma, Inc. engages in the development, manufacturing, and commercialization of traditional Chinese herbal medicines and biological pharmaceuticals in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Anbc, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.005 |
| 52 Week High | US$0.038 |
| 52 Week Low | US$0.005 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -96.43% |
| 5 Year Change | -85.92% |
| Change since IPO | -99.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| SYUP | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 2.6% | 0.5% |
| 1Y | n/a | 13.1% | 30.7% |
Return vs Industry: Insufficient data to determine how SYUP performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how SYUP performed against the US Market.
Price Volatility
| SYUP volatility | |
|---|---|
| SYUP Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SYUP has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SYUP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Wei Dong | n/a |
Shanghai Yutong Pharma, Inc. engages in the development, manufacturing, and commercialization of traditional Chinese herbal medicines and biological pharmaceuticals in the People’s Republic of China. Its products primarily include Qilisheng a product formulated to be a general health enhancer by fortifying the immune system; Qi-ju-di-huang, an oral solution that protects the kidney and the liver; Qing-re-jie-du, an oral solution that reduces fever and relieves heat; Sheng-mai-yin, a solution that protects energy and enhances body fluids; Xiao-qing-long, an oral solution that relieves cough and dyspnea; Shen-bao, a syrup for the treatment of impotence and spermatorrhoea; Ban-xia, a syrup that relieves cough; and Gan-mao-zhi-ke, a syrup that relieves flu symptoms, cough, and nasal congestion. It also offers Ban-lan-gen that relieves cold and flu symptoms; Gan-mao-qing-re that relieves minor body aches and pains, and reduces fever; Huang-dan-yin-chen used in the treatment for jaundice infection hepatitis; and Liu-shen-qu for treatment of vomitings and dysentery.
Anbc, Inc. Fundamentals Summary
| SYUP fundamental statistics | |
|---|---|
| Market cap | US$398.02k |
| Earnings (TTM) | -US$382.25k |
| Revenue (TTM) | US$50.95k |
0.0x
P/S Ratio0.0x
P/E RatioIs SYUP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SYUP income statement (TTM) | |
|---|---|
| Revenue | US$50.95k |
| Cost of Revenue | -US$27.85k |
| Gross Profit | US$78.80k |
| Other Expenses | US$461.04k |
| Earnings | -US$382.25k |
Last Reported Earnings
Dec 31, 2007
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did SYUP perform over the long term?
See historical performance and comparison